Search

Your search keyword '"Emilia Cotzia"' showing total 3 results
Start Over Author "Emilia Cotzia" Publication Type Academic Journals
3 results on '"Emilia Cotzia"'

1. Isatuximab, pomalidomide, and dexamethasone as salvage therapy for patients with multiple myeloma: the Italian, multicenter, retrospective clinical experience with 270 cases outside of controlled clinical trials

Author

Enrica Antonia Martino, Daniele Derudas, Elena Rossi, Sofia Terlizzi, Giovanni Reddiconto, Paola Stefanoni, Jacopo Micozzi, Silvia Mangiacavalli, Elena Zamagni, Massimo Offidani, Anna Furlan, Gabriele Buda, Flavia Lotti, Carmine Liberatore, Antonio Lazzaro, Roberta Della Pepa, Giuseppe Bertuglia, Emiliano Barbieri, Concetta Conticello, Claudio De Magistris, Lorenzo De Paoli, Velia Bongarzoni, Anna Maria Cafro, Anna Mele, Pietro Benvenuti, Claudio Cerchione, Cirino Botta, Elisabetta Antonioli, Nicola Sgherza, Sara Aquino, Giuseppe Mele, Gregorio Barilà, Salvatore Palmieri, Ombretta Annibali, Rosario Bianco, Massimiliano Arangio Febbo, Gloria Margiotta Casaluci, Angela Rago, Raffaele Fontana, Francesca Farina, Ernesto Vigna, Antonella Bruzzese, Katia Mancuso, Davide Nappi, Sonia Morè, Elena Rivolti, Catello Califano, Angela Amendola, Daniela Roccotelli, Alessandra Lombardo, Annalisa Citro, Giuseppina Uccello, Renato Zambello, Alessandro Maggi, Santo Neri, Michele Monachesi, Alessandro Gozzetti, Vittorio Montefusco, Marino Brunori, Emilia Cotzia, Giuseppe Pietrantuono, Angela Maria Quinto, Valeria Amico, Nicola Di Renzo, Marta Coscia, Monica Galli, Valerio De Stefano, Maria Teresa Petrucci, Antonino Neri, Francesco Di Raimondo, Fortunato Morabito, Pellegrino Musto, and Massimo Gentile

Subjects
Diseases of the blood and blood-forming organs, RC633-647.5
Abstract

Not available.

Published
2024
Full Text
View/download PDF

2. Elotuzumab plus pomalidomide and dexamethasone in relapsed/refractory multiple myeloma: a multicenter, retrospective, real-world experience with 200 cases outside of controlled clinical trials

Author

Massimo Gentile, Ernesto Vigna, Salvatore Palmieri, Monica Galli, Daniele Derudas, Roberto Mina, Roberta Della Pepa, Renato Zambello, Enrica Antonia Martino, Antonella Bruzzese, Silvia Mangiacavalli, Elena Zamagni, Catello Califano, Maurizio Musso, Concetta Conticello, Claudio Cerchione, Giuseppe Mele, Nicola Di Renzo, Massimo Offidani, Giuseppe Tarantini, Gloria Margiotta Casaluci, Angela Rago, Roberto Ria, Giuseppina Uccello, Gregorio Barilà, Gaetano Palumbo, Alessandra Pompa, Donatella Vincelli, Marino Brunori, Fabrizio Accardi, Valeria Amico, Angela Amendola, Raffaele Fontana, Velia Bongarzoni, Bernardo Rossini, Emilia Cotzia, Alessandro Gozzetti, Rita Rizzi, Nicola Sgherza, Eleonora Ferretti, Giuseppe Bertuglia, Davide Nappi, Maria Teresa Petrucci, Francesco Di Raimondo, Antonino Neri, Fortunato Morabito, and Pellegrino Musto

Subjects
Diseases of the blood and blood-forming organs, RC633-647.5
Abstract

In the ELOQUENT-3 trial, the combination of elotuzumab, pomalidomide and dexamethasone (EloPd) proved to have a superior clinical benefit over pomalidomide and dexamethasone with a manageable toxicity profile, leading to its approval for the treatment of patients with relapsed/refractory multiple myeloma (RRMM) who have received at least two prior therapies, including lenalidomide and a proteasome inhibitor. We report here a real-world experience of 200 cases of RRMM treated with EloPd in 35 Italian centers outside of clinical trials. In our dataset, the median number of prior lines of therapy was two, with 51% of cases undergoing autologous stem cell transplant and 73% having been exposed to daratumumab. After a median follow-up of 9 months, 126 patients had stopped EloPd, most of them (88.9%) because of disease progression. The overall response rate was 55.4%, a finding in line with the pivotal trial results. Regarding adverse events, the toxicity profile in our cohort was similar to that in the ELOQUENT-3 trial, with no significant differences between younger (

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results